8-K: XWELL Reports Fiscal Year 2024 Results: Revenue Up 13%, Gross Margin Doubles

XWELL, Inc. announces its fiscal year 2024 results, highlighting revenue growth, improved gross margins, and strategic expansion initiatives.

Summary

• XWELL, Inc. reported its financial results for the year ended December 31, 2024.
• The company achieved approximately 13% revenue growth compared to 2023.
• Gross margin more than doubled, increasing from 12.2% in 2023 to 26.3% in 2024.
• Operating expenses were reduced by approximately 19% compared to the previous year.
• A three-year extension of the Traveler-based Genomic Surveillance Program with the CDC was announced.
• XWELL launched a new Naples Wax Center in Estero, Florida, expanding beyond airport locations.
• The company closed a $4 million private placement in January 2025.
• Plans to acquire select medical spas to expand into the wellness and beauty sector were announced.
• XWELL intends to unite all wellness offerings under a single XWELL brand identity.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook, highlighting revenue growth, improved margins, and strategic expansion plans. While the company is still operating at a loss, the significant improvements compared to the previous year and the forward-looking statements suggest a positive trajectory.

Positives

• Revenue growth of approximately 13% indicates increasing demand for XWELL's services.
• The significant increase in gross margin, from 12.2% to 26.3%, suggests improved operational efficiency and pricing strategies.
• The reduction in operating expenses by approximately 19% demonstrates effective cost management.
• The CDC contract extension provides a stable revenue stream and validates XWELL's role in biosecurity.
• The $4 million private placement strengthens the company's capital structure and supports expansion plans.
• Expansion into the medical spa sector offers growth opportunities in the high-growth wellness and beauty market.
• The planned unification of all wellness offerings under the XWELL brand could enhance brand recognition and customer loyalty.

Negatives

• The company still reported an operating loss of approximately ($16.7) million for the year, although it is an improvement from the previous year's loss of ($28.2) million.
• The net loss attributable to XWELL was approximately ($16.9) million, an improvement from the previous year's loss of ($27.7) million, but still a loss.

Risks

• The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
• Reliance on the CDC contract for a significant portion of revenue exposes the company to potential funding or policy changes.
• Expansion into new markets and business lines carries inherent risks related to competition, execution, and market acceptance.
• The company's ability to achieve and maintain profitability depends on continued cost management and revenue growth.

Future Outlook

XWELL is focused on accelerating growth both in and out of airports, unifying its offerings under the XWELL brand, reinforcing its role in U.S. biosecurity, and exploring biosecurity opportunities outside of the United States, positioning the company for continued growth and long-term value creation.

Management Comments

• 'XWELL's improved 2024 financial and operational performance reflects the successful execution of our growth and productivity initiatives,' said Ezra Ernst, CEO of XWELL.
• Mr. Ernst added, 'Looking ahead, I'm excited about the opportunities ahead for XWELL.'

Industry Context

XWELL operates at the intersection of travel, health, and wellness, a growing market driven by increasing consumer awareness and demand for self-care and preventative health services. The company's expansion into medical spas aligns with the trend of integrating wellness and beauty services, while its biosecurity initiatives address the ongoing need for public health monitoring and protection.

Comparison to Industry Standards

• Comparing XWELL's revenue growth of 13% to other wellness and spa companies like Massage Envy (private) or franchised locations of larger brands, the growth rate is competitive, especially considering XWELL's focus on airport locations.
• The gross margin improvement to 26.3% is still lower than some established medical spa chains like The Woodhouse Day Spa (private), which often have gross margins exceeding 40% due to higher service prices and product sales.
• XWELL's biosurveillance program is unique and doesn't have direct competitors in the private sector, but its contract value can be compared to government contracts awarded to companies like Ginkgo Bioworks (DNA) for similar public health initiatives.

Stakeholder Impact

• Shareholders may benefit from the company's growth initiatives and improved financial performance.
• Employees may see increased opportunities as the company expands its operations.
• Customers can expect a more unified and accessible wellness experience under the XWELL brand.
• Suppliers may see increased demand for their products and services as the company grows.
• Creditors may view the company as a lower credit risk due to its improved financial performance and capital structure.

Next Steps

• Expand and integrate offerings across its brands.
• Unify airport and off-airport locations under the XWELL brand.
• Develop membership and loyalty programs.
• Broaden the retail product portfolio.
• Acquire select medical spas in metropolitan areas.
• Open an XpresSpa location in New York City's Penn Station.
• Open 6 additional Naples Wax Center locations across Florida.

Key Dates

Keywords

XWELL, wellness, XpresSpa, Naples Wax Center, XpresCheck, HyperPointe, financial results, revenue growth, gross margin, biosecurity, medical spas, CDC, genomic surveillance